|
[Related PubMed/MEDLINE]
Total Number of Papers: 306
|
|
|
|
|
[Display Entries]
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: ADA |
| Long Form |
: anti-drug antibodies |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
A novel approach to assess domain specificity of anti-drug antibodies to moxetumomab pasudotox, an immunotoxin with two functional domains. |
--- |
| 2 |
2020 |
Anti-infliximab antibodies: How to compare old and new data? |
--- |
| 3 |
2020 |
Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. |
ADAs, NAbs, TE-POS |
| 4 |
2020 |
Clinical trial of laronidase in Hurler syndrome after hematopoietic cell transplantation. |
6MWT, HCT, MPS IH |
| 5 |
2020 |
Criteria to Reevaluate Anti-drug Antibody Assay Cut Point Suitability in the Target Population. |
--- |
| 6 |
2020 |
Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial. |
IFX, RA, TP |
| 7 |
2020 |
Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial. |
MTX, s.c, SpA |
| 8 |
2020 |
Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbs. |
GCLP |
| 9 |
2019 |
A differential sex-specific pattern of IgG2 and IgG4 subclasses of anti-drug antibodies (ADAs) induced by glatiramer acetate in relapsing-remitting multiple sclerosis patients. |
ADAs, GA, MS |
| 10 |
2019 |
A Fit-for-Purpose Method for the Detection of Human Antibodies to Surface-Exposed Components of BMS-986263, a Lipid Nanoparticle-Based Drug Product Containing a siRNA Drug Substance. |
Abs, ECL, FFP, HSP47, LNP, MRD, PEG, QCs, siRNA |
| 11 |
2019 |
A generic method for the detection of polyethylene glycol specific IgG and IgM antibodies in human serum. |
CV, OTC, PEG |
| 12 |
2019 |
A Model-Based Approach to Quantify the Time-Course of Anti-Drug Antibodies for Therapeutic Proteins. |
--- |
| 13 |
2019 |
Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody. |
BCMA, NAb, sBCMA |
| 14 |
2019 |
Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression. |
AAV, mAbs |
| 15 |
2019 |
An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis. |
DAS28-CRP, OLE, RA, RP, SAEs, TEAEs |
| 16 |
2019 |
Anti-drug Antibody Assay Conditions Significantly Impact Assay Screen and Confirmatory Cut-Points. |
PC, SCP |
| 17 |
2019 |
Anti-drug Antibody Assay Validation: Improved Reporting of the Assay Selectivity via Simpler Positive Control Recovery Data Analysis. |
PC |
| 18 |
2019 |
Antidrug antibody detection for adalimumab depends on the type of assay used: an experimental approach to help clinicians interpret diagnostic data. |
ABT, All-neg, All-pos, ARIA, AS, ELISA |
| 19 |
2019 |
Antidrug antibody formation during tumor necrosis factor alpha inhibitor treatment of severe psoriatic patients in the real-life practice. |
TNF-alpha |
| 20 |
2019 |
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. |
anti-TNF, IBD, TDM |
| 21 |
2019 |
Appropriateness of Biologics in the Management of Crohn's Disease Using RAND/UCLA Appropriateness Methodology. |
--- |
| 22 |
2019 |
Assessing the long-term stability of anti-drug antibodies in method validation: what is the added value? |
--- |
| 23 |
2019 |
Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis. |
AUC, DMARDs, ROC, SpA |
| 24 |
2019 |
CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial. |
CBR, DCR, DOR, mCRC, ORR, OS, PFS |
| 25 |
2019 |
Depletion of interfering IgG and IgM is critical to determine the role of IgE in pegvaliase-associated hypersensitivity. |
CIC, HAEs, Phe, PKU |
| 26 |
2019 |
Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. |
IFN-beta |
| 27 |
2019 |
Differences in immunogenicity associated with non-product related variability: insights from two pharmacokinetic studies using GP2017, an adalimumab biosimilar. |
CIs, PK |
| 28 |
2019 |
Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center. |
ASDAS, DAS28, PsA, RA, sIFX, SpA |
| 29 |
2019 |
Elucidation of the statistical factors that influence anti-drug antibody cut point setting through a multi-laboratory study. |
--- |
| 30 |
2019 |
Evaluating a Multiscale Mechanistic Model of the Immune System to Predict Human Immunogenicity for a Biotherapeutic in Phase 1. |
PD, PK, Treg |
| 31 |
2019 |
Evaluation of in vitro Assays to Assess the Modulation of Dendritic Cells Functions by Therapeutic Antibodies and Aggregates. |
DC, MoDC |
| 32 |
2019 |
First-in-human, randomized dose-escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of PF-06480605 in healthy subjects. |
IBD, MAD, NAb, s.c, SAD, TL1A |
| 33 |
2019 |
Formation and glomerular deposition of immune complexes in mice administered bovine serum albumin: Evaluation of dose, frequency, and biomarkers. |
BSA, cCIC, CIC, IC |
| 34 |
2019 |
Generation, Characterization, and Quantitative Bioanalysis of Drug/Anti-drug Antibody Immune Complexes to Facilitate Dedicated In Vivo Studies. |
ICs, PK |
| 35 |
2019 |
HLA- and genotype-based risk assessment model to identify infantile onset pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA). |
GAA, iTEM, rhGAA |
| 36 |
2019 |
Immunogenicity assay development and validation for biological therapy as exemplified by ustekinumab. |
ELISA, IL, nADA, SPR, UST |
| 37 |
2019 |
Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. |
DT-EIA |
| 38 |
2019 |
Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis. |
DT-EIA, EIA |
| 39 |
2019 |
Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics. |
APC, CAR, IMD, MOA, PD-1 |
| 40 |
2019 |
In vitro human helper T-cell assay to screen antibody drug candidates for immunogenicity. |
hA33, mAb |
| 41 |
2019 |
Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis. |
RA |
| 42 |
2019 |
Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays. |
CD, ELISA, HMSA, TNF, UC |
| 43 |
2019 |
Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk. |
TE-ADA |
| 44 |
2019 |
Mitigating target interference in bridging immunogenicity assay with target-blocking reagents and mild basic pH. |
--- |
| 45 |
2019 |
Modelling of the Time-Varying Pharmacokinetics of Therapeutic Monoclonal Antibodies: A Literature Review. |
mAbs, PK |
| 46 |
2019 |
Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment With TNFalpha Antagonists. |
mAbs |
| 47 |
2019 |
Monoclonal antibodies for severe asthma: Pharmacokinetic profiles. |
mAbs |
| 48 |
2019 |
Multiplexed immunoassay approach to characterize antidrug antibody like specific reactivity. |
--- |
| 49 |
2019 |
Neutralising anti-drug antibodies in Fabry disease can inhibit endothelial enzyme uptake and activity. |
AGAL, ERT, FD |
| 50 |
2019 |
Neutralizing Antibody Assay Development with High Drug and Target Tolerance to Support Clinical Development of an Anti-TFPI Therapeutic Monoclonal Antibody. |
CLB, NAb |
| 51 |
2019 |
New insights on critical reagent optimization for antidrug antibody assays. |
--- |
| 52 |
2019 |
Perspectives on exploring hybrid LBA/LC-MS approach for clinical immunogenicity testing. |
LBA |
| 53 |
2019 |
PF-06881893 (Nivestymâ„¢), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen): Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers. |
ANC, AUEC, CD, HVs, PD, PK, US-Neupogen |
| 54 |
2019 |
Pharmacodynamics, safety, and immunogenicity of Pelmeg, a pegfilgrastim biosimilar in healthy subjects. |
ANC, PD |
| 55 |
2019 |
Pharmacokinetics of Human Recombinant Anti-Botulinum Toxin Antibodies in Rats. |
BoNT, IgG1 |
| 56 |
2019 |
Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults. |
TEAEs |
| 57 |
2019 |
Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials. |
CL, hs-CRP, IL, s.c, Vss |
| 58 |
2019 |
Post-transplant laronidase augmentation for children with Hurler syndrome: biochemical outcomes. |
HCT, IV-ERT, uGAG |
| 59 |
2019 |
Preclinical pharmacokinetics of a novel anti-c-Met antibody-drug conjugate, SHR-A1403, in rodents and non-human primates. |
ADC, DAR, IND, PK |
| 60 |
2019 |
Prediction of natalizumab anti-drug antibodies persistency. |
MSD, PK |
| 61 |
2019 |
Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs. |
--- |
| 62 |
2019 |
Report on the AAPS Immunogenicity Guidance Forum. |
AAPS, FDA, PCs |
| 63 |
2019 |
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years. |
TE-ADAs |
| 64 |
2019 |
Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis. |
--- |
| 65 |
2019 |
Therapeutic drug monitoring of biologics in psoriasis. |
TDM |
| 66 |
2019 |
Use of Ella to facilitate drug quantification and antidrug antibody detection in preclinical studies. |
--- |
| 67 |
2018 |
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. |
ACR20, PK, RA |
| 68 |
2018 |
A simple and cost-effective assay for measuring anti-drug antibody in human patients treated with Adalimumab. |
LOD |
| 69 |
2018 |
Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1. |
--- |
| 70 |
2018 |
Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis. |
mAbs |
| 71 |
2018 |
Assessment of the immunogenicity of residual host cell protein impurities of OsrHSA. |
HCPs, HSA, OsrHSA |
| 72 |
2018 |
Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials. |
CIC, HAE, Ig, PEG, Phe, PKU |
| 73 |
2018 |
Bead-extraction and heat-dissociation (BEHD): A novel way to overcome drug and matrix interference in immunogenicity testing. |
Ab, BEAD, BEHD, BEHD, NAb |
| 74 |
2018 |
Collaborative study using common samples to evaluate the performance of anti-drug antibody assays constructed by different companies. |
--- |
| 75 |
2018 |
Comparison of different immunoassay methods to detect human anti-drug antibody using the WHO erythropoietin antibody reference panel for analytes. |
BLI, ECL, EPO, SPR, WHO |
| 76 |
2018 |
Construction of Macaque Immune-Libraries. |
--- |
| 77 |
2018 |
Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay. |
CI-M6PR, ERTs, NAbs |
| 78 |
2018 |
Detection of Memory B Activity Against a Therapeutic Protein in Treatment-Naive Subjects. |
ASC, SFU |
| 79 |
2018 |
Development and effect of antibodies to anakinra during treatment of severe CAPS: sub-analysis of a long-term safety and efficacy study. |
AEs, CAPS, CRP, DSSS, PK, SAA |
| 80 |
2018 |
Development of an anti-EPO antibody detection kit based on lab-on-a-chip and bridging antibody technologies. |
PRCA |
| 81 |
2018 |
Discrimination of Anti-drug Antibodies With Neutralizing Capacity in Infliximab- and Adalimumab-Treated Patients: Comparison of the Homogeneous Mobility Shift Assay and the Affinity Capture and Elution Assay. |
ACE, ADAL, HMSA, IFX |
| 82 |
2018 |
Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment. |
CD, IBD, IFX, TL, UC |
| 83 |
2018 |
Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study. |
ADL, ETN, INF |
| 84 |
2018 |
Drug-induced Glomerulonephritis: The Spectre of Biotherapeutic and Antisense Oligonucleotide Immune Activation in the Kidney. |
ASO |
| 85 |
2018 |
Humoral Immune Response After Intravitreal But Not After Subretinal AAV8 in Primates and Patients. |
NHP, rAAV8, vg |
| 86 |
2018 |
IgG4 anti-infliximab in treated patients: Clinical impact and temporal evolution. |
IFX |
| 87 |
2018 |
Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab. |
TNF |
| 88 |
2018 |
Immunogenicity assessment of tbo-filgrastim in cancer patients receiving chemotherapy. |
--- |
| 89 |
2018 |
Immunogenicity of therapeutic protein products: current considerations for anti-drug antibody assay in Japan. |
--- |
| 90 |
2018 |
Immunogenicity testing of therapeutic antibodies in ocular fluids after intravitreal injection. |
IC |
| 91 |
2018 |
Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study. |
CSF, ERT, i.c.v, ML, NAb |
| 92 |
2018 |
Interferon-beta specific T cells are associated with the development of neutralizing antibodies in interferon-beta treated multiple sclerosis patients. |
IFN-beta, MS |
| 93 |
2018 |
Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNFalpha Monoclonal Antibody. |
MTX, PsA, TP-DI |
| 94 |
2018 |
Isolation and Characterization of Novel Phage Displayed scFv Fragment for Human Tumor Necrosis Factor Alpha and Molecular Docking Analysis of Their Interactions. |
TNF-alpha |
| 95 |
2018 |
Low Percentage of Signal Regulatory Protein alpha/beta+ Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients. |
AUC, DEMs, RA, ROC, SIRP, TNF |
| 96 |
2018 |
MAPPs for the identification of immunogenic hotspots of biotherapeutics; an overview of the technology and its application to the biopharmaceutical arena. |
MAPPs |
| 97 |
2018 |
Methotrexate and BAFF interaction prevents immunization against TNF inhibitors. |
AID, BAFFtg, MTX, TNFi, WT |
| 98 |
2018 |
Neutralizing anti-drug antibodies in Fabry disease have no obvious clinical impact? |
FD |
| 99 |
2018 |
Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects. |
AUC, AUC0-336, GMRs, PK |
| 100 |
2018 |
Pharmacokinetics and Exposure-Response Analysis of RG7667, a Combination of Two Anticytomegalovirus Monoclonal Antibodies, in a Phase 2a Randomized Trial To Prevent Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients. |
anti-CMV, PK |
|
A Search Service for Abbreviation / Long Form
